ArticleOncology letters2025

Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study.

Yumin Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.